Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 36

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 36
---
 former or current customers. Although we have no knowledge of any
such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. Even
if we are successful in defending against any such claims, any such litigation could be protracted, expensive, a distraction to our management
team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.

51

If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.

Our
unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing
on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition
among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar
to those of ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could
be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate
variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register its trademarks
and trade names and establish name recognition based on its trademarks and trade names, then we may not be able to compete effectively,
and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets,
domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and could adversely impact our financial condition or results of operations. 

Our
proprietary information may be lost, or we may suffer security breaches.

In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary
business information, personal data, and personally identifiable information of our clinical trial subjects and employees, in our data
centers and on our networks. The secure processing, maintenance, and transmission of this information is critical to our operations.
Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due
to employee error, malfeasance, or other disruptions. Although, to our knowledge, we have not experienced any such material security
breach to date, any such breach could compromise our networks